Where Are They Now? Lissy Hu Joins Ascend to Tackle Workforce Challenges
March 14th 2025Lissy Hu, M.D., MBA, CEO of Ascend Learning, was one of Managed Healthcare Executive’s 2022 Emerging Leaders in Healthcare winners. The editors caught up with Hu as part of our new “Where Are They Now?” series spotlighting the career paths of past emerging leaders.
Read More
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 14th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Improving Diagnosis and Treatment for Hidradenitis Suppurativa | AAD 2025
March 10th 2025At the 2025 American Academy of Dermatology (AAD) meeting, Steven Daveluy, M.D., associate professor and program director of dermatology at Wayne State University, discussed ongoing barriers to the early diagnosis of hidradenitis suppurativa and the latest advancements in treatment.
Read More
Pediatric Dermatology Looks Bright as New Treatments Bring Hope Amid Access Challenges | AAD 2025
March 8th 2025Larry Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children's Hospital, presented a session at the American Academy of Dermatology’s annual meeting in Orlando on some of the most pressing topics in pediatric dermatology.
Read More
Regeneron Canada Reaches New Agreement Deal for Cancer Drug Libtayo
March 7th 2025The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, according to a news release by Regeneron Canada.
Read More
Abrysvo Shows Strong Immune Response and Safety in Older Adults Over Two RSV Seasons
March 6th 2025Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.
Read More
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
March 5th 2025Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer worldwide, marking a nearly 60% increase from 2020, according to BeiGene.
Read More
The Benefits of 'Hands-on' Coaching for Type 1 Diabetes
March 4th 2025In this part 2 video series, Arti Masturzo, M.D., chief medical officer of CCS, shares how coaching those with type 1 diabetes can deliver both measurable health improvements such as significant reductions in A1C levels, and enhanced patient confidence by providing hands-on education and support. Masturzo also addressed how CCS collaborates with healthcare providers and insurers to integrate care, reduce fragmentation and improve adherence to monitoring and treatment through AI-driven efforts.
Read More
FDA Accepts sNDA for Zoryve Cream for Atopic Dermatitis Treatment in Young Children
February 26th 2025This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic dermatitis (AD) in children aged 2 to 5 years. The PDUFA target action date of October 13, 2025, is set for its decision on the application.
Read More
FDA Accepts NDA for Epioxa Eye Therapy
February 24th 2025After receiving the Day 74 letter, which outlines the FDA’s initial assessment of the application, the agency accepted Epioxa for review for efficacy and safety and plans to complete the process by October 20, 2025 under the Prescription Drug User Fee Act (PDUFA).
Read More
Cigna Healthcare Names Paul Virtell President of Supplemental Health Business
February 20th 2025In this role, Virtell will oversee the strategy, daily operations and expansion of Cigna Healthcare’s Supplemental Health division, which helps customers manage out-of-pocket expenses from serious illnesses or accidents.
Read More
FDA Accepts NDA for Gilead's New HIV Prevention Shot
February 18th 2025Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release.
Read More
Opzelura Topical Cream Drives Incyte's Record Growth in 2024 with 50% Revenue Surge
February 18th 2025Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S. that helps restore skin color for this condition. It’s also approved to treat mild to moderate atopic dermatitis in patients 12 and older who are not immunocompromised.
Read More
Cigna Reveals Multi-Year Plan to Simplify Healthcare, Boost Transparency and Improve Patient Support
February 3rd 2025This follows the company’s recent earnings call, where executives discussed the organization’s growth and future plans, highlighting its focus on serving the best interests of their consumers.
Read More